Synthesis and Pharmacological Evaluation of N-(3-(1H-Indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a Potent Antimitotic Agent
详细信息 查看全文
- 作者：Rupa S. Shetty ; Younghee Lee ; Bin Liu ; Arifa Husain ; Rhoda W. Joseph ; Yixin Lu ; David Nelson ; John Mihelcic ; Wenchun Chao ; Kristofer K. Moffett ; Andreas Schumacher ; Dietmar Flubacher ; Aleksandar Stojanovic ; Marina Bukhtiyarova ; Ken Williams ; Kyoung-Jin Lee ; Alexander R. Ochman ; Michael S. Saporito ; William R. Moore ; Gary A. Flynn ; Bruce D. Dorsey ; Eric B. Springman ; Ted Fujimoto ; Martha J. Kelly
- 刊名：Journal of Medicinal Chemistry
- 出版年：2011
- 出版时间：January 13, 2011
- 年：2011
- 卷：54
- 期：1
- 页码：179-200
- 全文大小：1440K
- 年卷期：v.54,no.1(January 13, 2011)
- ISSN：1520-4804
文摘
The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described. A functionalized dibromobenzene intermediate was used as a key scaffold, which when modified by sequential Suzuki coupling and Buchwald鈭扝artwig amination provided a flexible entry to 1,3,5-trisubstituted phenyl compounds. A 1H-indol-4-yl moiety at the 1-position was determined to be a critical feature for optimal potency. The compounds have been shown to induce cell cycle arrest at the G2/M phase and demonstrate efficacy in both cell viability and cell proliferation assays. The primary site of action for these agents is revealed by their colchicine competitive inhibition of tubulin polymerization, and a computational model has been developed for the association of these compounds to tubulin. An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model.